Definium Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Definium Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+8%Cash, after subtracting all debt, equals 8% of its market value (net cash).
Lower than 53% of Healthcare companies in United States.
Tangible Assets Ratio
95%Of every $100 the company owns, $95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 74% of Healthcare companies in United States.
Tangible Net Worth Ratio
94%Of every $100 of net worth, $94 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 78% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Definium Therapeutics, Inc. made a loss over the last year. Definium Therapeutics, Inc. owes $0.17 for every $1 it owns. Definium Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossDefinium Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.27The share price is 5.27 times Definium Therapeutics, Inc.'s book value per share, higher than 73% of Healthcare companies in United States.
Market cap
$4.8 BThe total market value of all of Definium Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 84% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$919 MWhat Definium Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.84Net worth divided by the number of shares. The share price of $36.00 is 5.3 times this, which is the P/B above.
Return on equity (ROE)
-64.1%Definium Therapeutics, Inc. lost 64.1% of its shareholders' money over the last year, lower than 59% of Healthcare companies in United States.
Owes vs Owns
0.17×Definium Therapeutics, Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Dividend yield
NoneDefinium Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossDefinium Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredDefinium Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashDefinium Therapeutics, Inc. held $371 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Definium Therapeutics, Inc.: $4.8 B ÷ $919 M (30 Jun 2026) = 5.3.
What is Definium Therapeutics, Inc.'s return on equity?
Definium Therapeutics, Inc. lost 64.1% of its shareholders' money over the last year, lower than 59% of Healthcare companies in United States.
How much does Definium Therapeutics, Inc. owe compared with what it owns?
Definium Therapeutics, Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Does Definium Therapeutics, Inc. pay a dividend?
No. Definium Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.